Skip to content
Head to head

AnaptysBio vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: ANAB · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

ANAB +101.2%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
ANABVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price46.63515.02
Change today-1.62%-1.08%
1-year return+85.7%+22.0%
Market cap$1.39B$130.58B
52-week range26.01 – 72.36412.27 – 568.67
Valuation
P/E (TTM)8.9833.14
P/E percentile, own 5-yr range93rd99th
P/B66.616.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)5.6015.32
Net profit (TTM)$166.49M$3.88B
Revenue (TTM)--$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+18.5%+11.8%
Gross margin--85.5%
Operating margin17.6%33.1%
Net margin-11.5%30.7%
Free cash flow (TTM)--$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership110.5%96.8%
Insider activity (12mo)14 buy / 36 sell28 buy / 22 sell
Short interest (% of float)16.9%1.9%
Analyst consensus100% buy (7)95% buy / 5% hold (21)
Analyst price target$80 (+72%)$624 (+21%)
StockVane view
StockVane Quant RatingD (96)C (68)
Company
Employees1046,400
Founded20051989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.